个人简介
Mark Lemmon, PhD was appointed the Co-Director of the Cancer Biology Institute and the David A. Sackler Professor of Pharmacology in 2015. Dr. Lemmon returns to Yale, where he completed his PhD in 1993, from the University of Pennsylvania’s Perelman School of Medicine. At UPenn, he was the George W. Raiziss Professor of Biochemistry and Biophysics as well as Chair of the department and an Investigator at the Abramson Family Cancer Research Institute. Dr. Lemmon’s research focuses on the signaling pathways of receptor tyrosine kinases (RTKs), which, when mutated cause cancers and other diseases.
PhD Yale University (1993)
BA Oxford University (Hertford College), Biochemistry (1988)
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
The Dark Side of Cell Signaling: Positive Roles for Negative Regulators.
Lemmon MA, Freed DM, Schlessinger J, Kiyatkin A. (2016) Cell 164, 1172-84
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, Li Y, Zou HY, Lee NV, Smeal T, Lemmon MA, Mossé YP. (2016) Cancer Discovery 6, 96-107
Ligand regulation of a constitutively dimeric EGF receptor
Freed DM, Alvarado D, Lemmon MA. (2015) Nature Communications 6, 7380
Comparison of Saccharomyces cerevisiae F-BAR domain structures reveals a conserved inositol phosphate binding site.
Moravcevic K, Alvarado D, Schmitz KR, Kenniston JA, Mendrola JM, Ferguson KM, Lemmon MA. (2015) Structure 23, 352-63
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. (2014) Cancer Cell ,26 682-94.
Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.
Bessman NJ, Bagchi A, Ferguson KM, Lemmon MA. (2014) Cell Reports 9, 1306-17.
京公网安备 11010802027423号